Nurix Therapeutics Up Over 18%, on Pace for Larget Percent Increase Since June 2024 -- Data Talk

Dow Jones12-09 00:17

Nurix Therapeutics, Inc. (NRIX) is currently at $21.44, up $3.36 or 18.55%

 

--Would be highest close since Dec. 10, 2024, when it closed at $22.06

--On pace for largest percent increase since June 18, 2024, when it rose 20.6%

--Currently up four consecutive days; up 31.16% over this period

--Longest winning streak since Nov. 24, 2025, when it rose for four straight trading days

--Best four day stretch since the four days ending Nov. 24, 2025, when it rose 35.25%

--Up 21.3% month-to-date

--Up 13.83% year-to-date

--Down 57.26% from its all-time closing high of $50.17 on Jan. 19, 2021

--Up 3.8% from 52 weeks ago (Dec. 9, 2024), when it closed at $20.66

--Down 2.79% from its 52-week closing high of $22.06 on Dec. 10, 2024

--Up 160.25% from its 52-week closing low of $8.24 on Sept. 23, 2025

--Traded as high as $22.50; highest intraday level since Dec. 11, 2024, when it hit $22.95

--Up 24.38% at today's intraday high; largest intraday percent increase since April 9, 2024, when it rose as much as 26.88%

 

All data as of 11:14:12 AM ET

 

Source: Dow Jones Market Data, FactSet

 

(END) Dow Jones Newswires

December 08, 2025 11:17 ET (16:17 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment